1. From DNA Damage to Cancer Progression: Potential Effects of Cytolethal Distending Toxin
   Yi-Ru Lai et al, 2021, Frontiers in Immunology CrossRef
2. The Therapeutic Potential of Targeting Autophagy in the Treatment of Cancer
   Negin Chaeichi-Tehrani et al, 2021, Current Cancer Drug Targets CrossRef
3. Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38αKinase
   Valentina Grossi et al, 2012, Journal of Oncology CrossRef
4. Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway
   Mathieu Chocry et al, 2017, Oncotarget CrossRef
5. Hyaluronic Acid Layered Chimeric Nanoparticles: Targeting MAPK-PI3K Signaling Hub in Colon Cancer Cells
   Sandeep Palvai et al, 2017, ACS Omega CrossRef
6. GSTs, MRP and Apoptototic Markers in DLD-1 Human Colon Cancer Cell Line Before and After 5-FU Treatment
   Fatıma Nurdan GÜRBÜZ et al, 2022, International Journal of Nature and Life Sciences CrossRef
7. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway
   Chen Huang et al, 2023, Biological and Pharmaceutical Bulletin CrossRef
8. Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers
   Giulia Bon et al, 2017, Oncotarget CrossRef
9. Novel Potent EGFR-JAK3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in Colorectal Cancer
   Lixue Chen et al, 2023, Anti-Cancer Agents in Medicinal Chemistry CrossRef
10. p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
    Valentina Grossi, 2014, World Journal of Gastroenterology CrossRef
11. p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story
    Jesús García-Cano et al, 2016, Frontiers in Cell and Developmental Biology CrossRef
12. Overcoming P-Glycoprotein-Mediated Doxorubicin Resistance
    Suree Jianmongkol, 2021, Advances in Precision Medicine Oncology CrossRef